Articles Tagged With: Menopause
-
Targeting Vasomotor Symptoms with a Neurokinin-3 Receptor Antagonist
A meta-analysis of five randomized controlled studies showed that fezolinetant improved moderate-to-severe vasomotor symptoms with a pooled mean difference of 2.62 episodes per day (95% confidence interval [CI], 1.85-3.41) and had no significant adverse effects compared to placebo (odds ratio, 1.01; 95% CI, 0.84-1.22).
-
How Does the Genitourinary Syndrome of Menopause Affect Patients?
This analysis of baseline questionnaire responses from 302 individuals enrolled in the MsFLASH Vaginal Health Trial demonstrated that the most commonly reported symptoms were vaginal dryness (94%), pain with vaginal penetration (84%), vulvovaginal pain and soreness (76%), and vulvovaginal irritation (73%). The symptom most often rated severe was pain with vaginal penetration (40%).
-
Integrating Reproductive History Could Help Postmenopausal Women’s Long-Term Brain Health
Researchers observed patients with higher cumulative estrogen exposure throughout their life may be at lower risk of developing cerebral small vessel disease.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
More than 500 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment vs. placebo.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.
-
Fezolinetant Tablets (Veozah)
Fezolinetant can be prescribed to treat moderate-to-severe vasomotor symptoms caused by menopause.
-
Oral Medication to Treat ‘Hot Flashes’ Could Be Available Soon
The FDA has approved the first neurokinin 3 receptor antagonist to alleviate symptoms associated with moderate to severe vasomotor symptoms caused by menopause.
-
Hormonal Contraceptives Help Women Manage Perimenopause
Women near the end of their reproductive years may experience fewer perimenopausal symptoms if they use a hormonal contraceptive, such as a hormonal intrauterine device.
-
Do Anti-Müllerian Hormone Levels Decline More Rapidly After Hysterectomy with Ovarian Conservation?
In this multi-site, community-based study, anti-Müllerian hormone levels did not decline more rapidly among patients who underwent hysterectomy with ovarian conservation compared to patients who experienced natural menopause.
-
Is Vaginal Carbon Dioxide Laser an Effective Treatment for the Genitourinary Syndrome of Menopause?
In this double-blinded, randomized controlled trial, fractional carbon dioxide vaginal laser was no better than sham laser in improving Female Sexual Function Index scores among 72 breast cancer survivors on aromatase inhibitors over a six-month period.